Tailoring the right team is crucial to project success.
Our consultants are an experienced, highly educated multidisciplinary team with broad disease area backgrounds and extensive, practical market access knowledge, who are curious about and engaged in what they do; your key contact will be a senior member of the consultancy team. In addition, all work is reviewed by our quality review team, drawn from senior leadership roles in pharmaceutical and biotech companies, the payer community, and from academia; our quality review team oversees all work in progress to ensure that it answers your needs and tells the whole story.
International experts group
This agile team has organized, moderated, and facilitated more than 55 advisory boards and expert panels over the past 3 years, and maintains strong working relationships with more than 700 payer and clinician advisors.
This team comprises consultants, many of whom are native-language speakers, with specific knowledge of HTA/P&R processes and healthcare systems in core and key emerging markets, ensuring that project analysis and insights are framed appropriately within the rapidly evolving P&R landscape.
We have a unique program approval in place with a duly constituted university ethics committee, ensuring that studies are methodologically rigorous and meet the requirements for publication in peer-reviewed journals.